BAYN.DE
BuySecond WindAI neutralBayer Aktiengesellschaft · Healthcare · Germany · $55.2B
EUR 42.59 -3.1% · close 8 Oct · scored 10 Oct
StockRank down 1.2 since 9 Oct.
Second Wind: Cheap and rising again, but the business does not yet earn the optimism.
Read our full research report on BAYN.DE (Jun 2026), freeAs of 10 Oct 2026, MoatMap's StockRank for Bayer Aktiengesellschaft (BAYN.DE) is 70/100, ranked against 24,000+ stocks in 35 markets (Quality 45, Value 57, Momentum 61, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Bayer combines a large crop science business, a pharmaceuticals division and consumer health. Higher grain prices can support demand for seeds and crop protection, and the share price has recovered from depressed levels. The company still carries heavy debt and long-running US glyphosate litigation liabilities, and faces patent expiries in pharma, so the case rests on a restructuring rather than a proven compounder.
ABOUT BAYER AKTIENGESELLSCHAFT
Read
Bayer Aktiengesellschaft is a global life science company with core competencies in healthcare and agriculture, developing and marketing pharmaceutical products, consumer health items, and crop science solutions. Its extensive R&D capabilities, strong brand recognition, and diversified portfolio across these sectors provide a significant competitive moat. Bayer is a major multinational innovator in life sciences, balancing pharmaceutical development with agricultural advancements.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.7B | 47.6B | 46.6B | 45.6B | -3.5% | 45.4B | 45.9B | 47.1B | 1.6% |
| EPS (EUR) | 4.22 | -2.99 | -2.60 | -3.68 | — | -1.75 | — | — | — |
| Shares | 982.4M | 982.4M | 982.4M | 982.4M | 0.0% | 982.4M | — | — | — |
| Debt | 41.3B | 42.9B | 40.7B | 36.5B | -4.1% | 38.4B | — | — | — |
| Equity | 38.8B | 32.9B | 31.9B | 25.9B | -12.5% | — | — | — | — |
| Op CF | 7.1B | 5.1B | 7.4B | 5.9B | -5.8% | 4.8B | — | — | — |
| Inv CF | -2.4B | -3.5B | 164.0M | -1.3B | — | — | — | — | — |
| Fin CF | -4.2B | -679.0M | -7.2B | -3.9B | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 52% of stocks we rank over the past year (42% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BAYN.DE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BAYN.DE | Bayer Aktiengesellschaft(you) | $55.2B | 70 | Buy |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $69.4B | 67 | Buy |
| BIIB | Biogen Inc. | $33.6B | 80 | Strong Buy |
| GSK.L | GSK plc | $100.0B | 84 | Strong Buy |
| 4568.T | Daiichi Sankyo Company, Limited | $33.3B | 51 | Hold |
| 4578.T | Otsuka Holdings Co., Ltd. | $36.6B | 92 | Strong Buy |
| SAN.PA | Sanofi | $99.7B | 90 | Strong Buy |
| NVO | Novo Nordisk A/S | $168.6B | 80 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $187.7B | 79 | Buy |
| AZN.L | AstraZeneca PLC | $255.1B | 75 | Buy |
Peer medians: ROE 3.0% · P/E 23.9x · Gross margin 53.9%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.